Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Tekturna Is First Renin Inhibitor Approved For Hypertension

This article was originally published in The Pink Sheet Daily

Executive Summary

The first-in-class drug will launch later in March.

You may also be interested in...



Novartis Plans To Buy Back Speedel For $880 Million

Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.

Novartis Plans To Buy Back Speedel For $880 Million

Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.

Tekturna Shows Non-Inferiority To Merck’s Cozaar On Left Ventricular Hypertrophy

Combination of both medicines, however, did not achieve a statistically significant reduction in LVH over losartan alone.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel